|
Jul 29
|
Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.
|
|
Jul 26
|
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
|
|
Jul 25
|
SAGALIUM RESPONDS TO COMPETITOR’S FALSE AND MISLEADING PRESS RELEASE
|
|
May 22
|
Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation
|
|
May 2
|
Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment
|
|
Mar 25
|
ENZOLYTICS, INC. SHAREHOLDERS HOLD SPECIAL MEETING AND ELECT NEW BOARD
|
|
Jan 16
|
Enzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on Longevity
|
|
Sep 6
|
Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")
|
|
Sep 5
|
Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.
|
|
Aug 24
|
Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
|
|
Aug 8
|
Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment
|
|
Jun 29
|
Enzolytics, Inc. Reports Amendment to Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp.
|